← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN › TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN › Antiinflammatory preparations, non-steroids for topical use
suxibuzone
M02AA22
Forms & Strengths
- Oral capsules 200 mg
- Oral tablets 200 mg
Adult Dosing
- 300 mg to 600 mg daily administered in divided doses
- Maximum daily dose generally should not exceed 600 mg
- Use lowest effective dose for the shortest duration necessary
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
- Not recommended for use in children
Indications
- Treatment of painful and inflammatory conditions of the musculoskeletal system
- Short-term management of osteoarthritis and rheumatoid arthritis
- Management of acute musculoskeletal disorders such as tendonitis and bursitis
Mechanism of Action
- Pro-drug of phenylbutazone
- Inhibits cyclooxygenase (COX-1 and COX-2) enzymes
- Reduces the synthesis of pro-inflammatory prostaglandins from arachidonic acid
- Exhibits anti-inflammatory, analgesic, and antipyretic properties
Contraindications
- Active peptic ulcer disease or history of recurrent gastrointestinal ulceration
- Severe hepatic, renal, or cardiac impairment
- Hypersensitivity to suxibuzone, phenylbutazone, or other NSAIDs
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Conditions involving an increased bleeding tendency or active hemorrhage
Adverse Reactions
- Gastrointestinal distress, nausea, dyspepsia, and gastric ulceration
- Increased risk of gastrointestinal bleeding and perforation
- Fluid retention, edema, and hypertension
- Hepatotoxicity with elevated liver enzymes
- Hematological abnormalities including leukopenia, thrombocytopenia, and aplastic anemia
- Skin rashes and hypersensitivity reactions
Drug Interactions
- Concomitant use with oral anticoagulants (e.g., warfarin) increases the risk of severe bleeding
- Increased risk of gastrointestinal ulceration when combined with corticosteroids or other NSAIDs
- May diminish the antihypertensive effect of ACE inhibitors, ARBs, and diuretics
- Increased plasma concentrations and toxicity risk of lithium and methotrexate
- Enhanced hypoglycemic effects when administered with oral hypoglycemic agents or insulin
Curated Content: Needs Vetting Before Put to Clinical Use